GEOGRAPHIC ATROPHY
Clinical trials for GEOGRAPHIC ATROPHY explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug syfovre under Real-World safety watch for blinding disease
Disease control OngoingThis study follows about 300 people with geographic atrophy, a late stage of age-related macular degeneration that causes vision loss, who are prescribed Syfovre (pegcetacoplan) by their doctor. Researchers will track side effects and how the drug is used in routine care over tim…
Matched conditions: GEOGRAPHIC ATROPHY
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 15:00 UTC
-
New eye injection aims to slow vision loss from dry AMD
Disease control OngoingThis early-stage study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a severe form of dry age-related macular degeneration). The study involves 27 participants and will monitor side effects and eye health…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 17, 2026 14:58 UTC
-
New eye injection shows promise against blinding disease
Disease control OngoingThis study tests a new medicine, BI 771716, against an existing treatment (pegcetacoplan) for geographic atrophy, a progressive eye disease that causes vision loss. About 202 adults aged 50 and older will receive eye injections every 4 weeks for over a year. The goal is to see if…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 17, 2026 14:55 UTC
-
New drug aims to slow blindness from dry AMD
Disease control OngoingThis study tests an experimental drug called tinlarebant in 429 adults with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The goal is to see if the drug can slow the growth of damaged areas in the eye and preserve vision. Pa…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New eye drug shows promise for blinding disease
Disease control OngoingThis early-stage study tests a new drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections of K8 and be monitored for 26 weeks to check safety…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Michelle Abou-Jaoude • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug aims to halt blinding eye disease in older adults
Disease control OngoingThis study tests an experimental drug, BI 1584862, to see if it can slow the worsening of geographic atrophy, a leading cause of blindness in older adults. About 150 people aged 50 and older with this eye condition will receive either the drug or a placebo for one year. Doctors w…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New eye drug aims to halt vision loss in common blinding disease
Disease control OngoingThis study tests whether monthly eye injections of a drug called ANX007 can prevent significant vision loss in people with dry age-related macular degeneration (AMD) that has progressed to geographic atrophy. About 659 participants will receive either the drug or a sham injection…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Gene therapy trial targets blinding eye disease
Disease control OngoingThis study tests a new treatment called OCU410 for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. The trial involves 60 adults aged 50 and older and aims to see if the treatment is safe and can slow the growth of dam…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
Sound-Based eye trainer could sharpen vision scans
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new device that uses sound to help people with vision loss keep their eyes still during eye exams. About 22 healthy volunteers and patients with retinal disease will try to focus on a target while a camera tracks their eye movements. The goal is to see if real-…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: NA • Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated May 17, 2026 14:54 UTC